Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer.
OBJECTIVE
To determine the activity and toxicities of low dose leucovorin (LV) plus fluorouracil (5-FU) regimen, combined with oxaliplatin every two weeks (modified FOLFOX 4), as a first-line therapy for patients with metastatic colorectal cancer.


METHODS
Between March 2001 and August 2003, fifty-five patients were enrolled in this study. Patients were treated with oxaliplatin 85 mg/m(2) as a 2-hour infusion at days 1 plus LV 20 mg/m(2) over 10 minutes, followed by 5-FU bolusa 400 mg/m(2) bolus and 22 hour continuous infusion of 600 mg/m(2) 5-FU at day 1 approximately 2. This treatment was repeated in 2 week intervals.


RESULTS
The objective response rate was 40% on an intent-to-treatment analysis. Three patients (6%) demonstrated a complete response and nineteen patients (38%) showed a partial response. Sixteen patients (32%) showed a stable disease and eleven patients (22%) progressed during the course of the treatment. The median time to progression and overall survival time were as 6.6 months (95% CI: 4.98 approximately 8.02 months) and the median overall survival time was 17.0 months (95% CI: 9.15 approximately 24.85 months) from the start of the chemotherapy, respectively. A total of 275 cycles were analyzed for toxicity. Major hematologic toxicities included grade 1 approximately 2 anemia (23.5%), neutropenia (25.3%) and thrombocytopenia (10.6%). There were only 2 cycles of neutropenic fever. The most common non-hematologic toxicities were grade 1 approximately 2 nausea/vomiting (10.9%), diarrhea (9.1%) and grade 1 neuropathy (18.0%). There was no treatment related death.


CONCLUSIONS
The modified folfox 4 regimen is safe and effective regimen as a first-line therapy in advanced colorectal cancer patients.
Kwon
Hyuk-Chan
HC
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Kim
Kyoung Tae
KT
Lee
Shin Ae
SA
Park
Jong-Sung
JS
Kim
Sung-Hyun
SH
Kim
Jae-Seok
JS
Kim
Hyo Jin
HJ
Lancet. 2000 Mar 25;355(9209):1041-7
10744089
Eur J Cancer. 1997 Feb;33(2):214-9
9135491
J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17
7932825
Ann Oncol. 1996 Jan;7(1):95-8
9081400
Cancer Res Treat. 2002 Dec;34(6):405-8
26680895
J Clin Oncol. 2003 Aug 1;21(15):2904-11
12885808
J Clin Oncol. 2000 Jan;18(1):136-47
10623704
Br J Cancer. 2000 Jun;82(11):1789-94
10839292
J Clin Oncol. 1998 Aug;16(8):2739-44
9704726
Eur J Cancer. 2001 Dec;37(18):2457-63
11720843
J Clin Oncol. 2000 Aug;18(16):2938-47
10944126
Oncology. 2006;70(3):222-30
16816536
Eur J Cancer. 2001 May;37(8):1000-5
11334725
Anticancer Drugs. 1997 Oct;8(9):876-85
9402315
Cancer Res Treat. 2002 Jun;34(3):218-22
26680866
J Clin Oncol. 2002 Oct 1;20(19):4006-14
12351598
J Clin Oncol. 2002 Aug 15;20(16):3478-83
12177109
J Clin Oncol. 2002 Apr 1;20(7):1759-66
11919232
Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33
12422305
Br J Cancer. 2001 Jan 5;84(1):1-7
11139304